Understand the source comparison
How to Use Peptides for Gut Inflammation: Protocol Comparison
This table compares the three primary peptides used in gut inflammation research protocols, detailing mechanisms, dosing, and clinical application. BPC-157 Upregulates VEGF, promotes angiogenesis, stabilises gastric mucosa 250–500mcg once daily Structural muco
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares the three primary peptides used in gut inflammation research protocols, detailing mechanisms, dosing, and clinical application.
- BPC-157
- Upregulates VEGF, promotes angiogenesis, stabilises gastric mucosa
- 250–500mcg once daily
- Structural mucosal damage, ulcers, fistulas, permeability defects
- Animal studies show accelerated healing of gastric and duodenal ulcers within 14 days
- Requires continuous daily dosing during active repair phase
- KPV
- Inhibits NF-κB nuclear translocation, blocks cytokine transcription
- 500–1000mcg once daily
- Cytokine-driven inflammation without structural damage, Crohn's flares, dysbiosis
- In vitro studies demonstrate 60% reduction in TNF-α and IL-6 secretion in activated macrophages
- More effective when inflammation is cytokine-mediated rather than structural
- Thymalin
- Modulates T-cell function in GALT, promotes immune tolerance
- 5–10mg every other day
- Autoimmune-driven gut inflammation, immune dysregulation, IBD with positive serology
- Clinical trials in Russia showed reduced disease activity scores in ulcerative colitis patients
- Requires longer treatment duration (8–12 weeks) to observe immune modulation effects